溃疡性结肠炎患者储袋炎及储袋相关并发症的发生率、危险因素与结局
基于2007至2016年IQVIA行政理赔数据库,594例溃疡性结肠炎行回肠储袋肛管吻合术患者中,术后2年储袋炎累积发生率为48%(95%CI 44%-52%),孤立性急性储袋炎为29%,复发性储袋炎为19%;复发性储袋炎患者门诊、急诊和住院均增加(均P<.001)。
要点
- 溃疡性结肠炎回肠储袋肛管吻合术后2年内储袋炎累积发生率为48%(95%CI 44%-52%)。
- 复发性储袋炎患者较孤立性急性储袋炎患者门诊、急诊和住院均增加(均P<.001)。
- 储袋炎患者中新免疫抑制治疗累积频率为40%(95%CI 35%-46%)。
核心结论
- 在地理分布多样的人群中,48%的溃疡性结肠炎患者在回肠储袋肛管吻合术后2年内发生储袋炎。
- 储袋炎患者医疗资源使用更多,提示疾病负担显著。
研究设计与样本
- 基于IQVIA Legacy PharMetrics Adjudicated Claims Database的行政理赔数据分析,纳入2007年1月1日至2016年6月1日期间因溃疡性结肠炎行直肠结肠切除术联合回肠储袋肛管吻合术的全部患者,共594例。
主要发现
- 594例患者中,回肠储袋肛管吻合术后2年内储袋炎累积发生率为48%(95%CI 44%-52%)。
- 孤立性急性储袋炎累积发生率为29%(95%CI 26%-33%),复发性储袋炎累积发生率为19%(95%CI 16%-22%)。
- 与孤立性急性储袋炎患者相比,复发性储袋炎患者门诊就诊、急诊就诊和住院均增加(均P<.001)。
- 发生储袋炎的患者更可能有原发性硬化性胆管炎病史(aOR 3.94;95%CI 1.05-14.8)和结肠切除术前抗肿瘤坏死因子α治疗史(aOR 1.63;95%CI 1.09-2.45)。
- 储袋炎患者中新免疫抑制治疗累积频率为40%(95%CI 35%-46%),储袋切除累积发生率为1.0%(95%CI 0.4%-3.0%),溃疡性结肠炎回肠储袋肛管吻合术后新诊断克罗恩病的累积发生率为9.0%(95%CI 7.2%-11%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA. METHODS: We identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital. RESULTS: Among 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%). CONCLUSIONS: In a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
引用
- Barnes EL, Herfarth HH, Kappelman MD, et al. Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32585362. doi:10.1016/j.cgh.2020.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。